Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yugo Narumi"'
Autor:
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities
Externí odkaz:
https://doaj.org/article/8a2b28555c90401aa5082f21d4b9f7f8
Autor:
Kooijman, Jeffrey J., van Riel, Wilhelmina E., Dylus, Jelle, Prinsen, Martine B. W., Grobben, Yvonne, de Bitter, Tessa J. J., van Doornmalen, Antoon M., Melis, Janneke J. T. M., Uitdehaag, Joost C. M., Yugo Narumi, Yusuke Kawase, de Roos, Jeroen A. D. M., Willemsen-Seegers, Nicole, Zaman, Guido J. R.
Publikováno v:
Frontiers in Oncology; 9/14/2022, Vol. 12, p1-22, 22p
Autor:
Martine B.W. Prinsen, Michelle Muller, Jeffrey J. Kooijman, Yugo Narumi, Yvonne Grobben, Guido J.R. Zaman, Rogier C. Buijsman, Jelle Dylus, Wilhelmina E. van Riel, Jos de Man, Yusuke Kawase, Jeroen A.D.M. de Roos, Suzanne J.C. van Gerwen, Nicole Willemsen-Seegers
Publikováno v:
Cancer Research. 81:1480-1480
Kinases are the major anticancer drug target class of the 21st century with nearly sixty small molecule kinase inhibitors approved for clinical use in the first two decades. While there are more than 500 kinases encoded by the human genome, currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d67d2c8a8f49611f5a0aaafa943fee15
https://doi.org/10.1158/1538-7445.am2021-1480
https://doi.org/10.1158/1538-7445.am2021-1480
Autor:
Kensaku Akita, Hiroshi Ohmoto, Eiji Nishiwaki, Koichi Yokota, Masaki Gouda, Yugo Narumi, Yasuyuki Kirii, Daisuke Kitagawa
Publikováno v:
Genes to Cells. 18:110-122
The specificities of nine approved tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, and pazopanib) were determined by activity-based kinase profiling using a large panel of human recom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f853d18fadece6055167ba1af93b6136
https://doi.org/10.1111/gtc.12022
https://doi.org/10.1111/gtc.12022
Autor:
Yasuyuki Kirii, Daisuke Kitagawa, Yugo Narumi, Masaki Gouda, Ikuo Fujii, Koichi Yokota, Naoyuki Sugiyama, Kensaku Akita, Yasushi Ishihama
Publikováno v:
Journal of Biochemistry. 151:47-55
It is known that some kinase inhibitors are sensitive to the phosphorylation state of the kinase, and therefore those compounds can discriminate between a phosphorylated and unphosphorylated protein. In this study, we prepared two colony stimulating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8afe42e5d7a382d8239223c563dbd9
https://doi.org/10.1093/jb/mvr112
https://doi.org/10.1093/jb/mvr112